Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01309048
Other study ID # 02082011
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received March 2, 2011
Last updated August 28, 2012
Start date January 2011
Est. completion date June 2012

Study information

Verified date August 2012
Source Philips Healthcare
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

This study is to confirm the safety and technical of MRI guided High Intensity Focused Ultrasound (HIFU) for Palliation for Pain of Skeletal Metastases.

MRI guided high intensity focused ultrasound uses ultrasound to heat and thermally ablate tissue. The MRI system identifies the ultrasound path and monitors heat rise in the tissue. The goal of the study is to show treatment safety and effectiveness. MR-guided HIFU will be performed in patients who pass inclusion/exclusion criteria.


Description:

Bone metastases are common among patients with advanced cancer and have been reported in up to 85% of cancer patients at autopsy. Complications of bone metastases include pain, functional limitation, decreased quality of life, pathological fracture, spinal cord compression and cauda equina syndrome.

External beam radiotherapy is the current standard treatment for patients with painful uncomplicated bone metastases. Unfortunately up to 30 % of patients treated with radiotherapy do not respond to therapy, and 30% of responders have their pain recur at some point after treatment. Radiotherapy re-treatment is also limited by cumulative doses delivered to sensitive structures. Ablative techniques such as cryotherapy and percutaneous radiofrequency ablation are not similarly limited by cumulative effects, however, they are invasive procedures that place patients at risk of complications.

MR-guided high intensity focused ultrasound (MR-HIFU) is a non-invasive, outpatient modality being investigated for the treatment of cancer. In MR-HIFU, a specially designed transducer is used to focus a beam of ultrasound energy into a small volume at a specific target site in the body. The focused beam produces therapeutic hyperthermia in the target field but only harmlessly warms the immediately surrounding tissue. Magnetic resonance (MR) imaging is used both to focus the ultrasound beam on the target field in the bone (the metastatic lesion and adjacent periosteum containing the nerves and vasculature for the tumor) and to perform real-time thermal mapping at and around the target. The mechanism of action of pain response is thought to be thermal periosteal denervation and / or thermal ablation of the tumor mass that diminishes pressure on the surrounding tissue.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age =18 years

- Able to give informed consent

- Weight <140kg

- Radiologic evidence of bone metastases from any solid tumor

- Able to characterize pain specifically at the site of interest (target lesion)

- Pain score related to target lesion of =4 on a 0-10 point scale irrespective of medications

- Target lesion accessible for MR-HIFU procedure

- Target lesion maximum dimension =8cm

- Target lesion is uncomplicated (i.e.: no fracture / spinal cord compression / cauda equina syndrome / soft tissue component)

- Target lesion visible by non-contrast MRI

- Interface between bone and skin lies =1cm from surface

- Able to communicate sensation during MR-HIFU treatment

- MR-HIFU treatment date =2 weeks from most recent treatment of primary tumor or any chemotherapy.

Exclusion Criteria:

- Prior radiotherapy / surgery / ablative therapy / other local therapy to target lesion.

- Unable to characterize pain specifically at the site of interest (target lesion)

- Pregnant / Nursing woman

- Target lesion is complicated (i.e.: presence of one of fracture / spinal cord compression / cauda equina syndrome / soft tissue component).

- Target lesion <1cm from nerve bundles / bladder / bowel

- Target lesion in contact with hollow viscera

- Target lesion located in skull, spine (excluding sacrum which is allowed) or sternum

- Scar along proposed HIFU beam path

- Orthopaedic implant along proposed HIFU beam path or at site of target lesion.

- Serious cardiovascular, neurological, renal or hematological chronic disease

- Active infection

- Unable to tolerate required stationary position during treatment

- Allergy to MRI contrast agent or sedation

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Philips MR-guided HIFU system
HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.

Locations

Country Name City State
Canada Sunnybrook Health Sciences Centre Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
Philips Healthcare

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol. 2002 Sep;64(3):275-80. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction of Pain Score Determine the efficacy of MR-Guided HIFU in reducing pain scores related to the site treated as measured on the Brief Pain Inventory (BPI). 90 Days No
Primary Reduction of Pain Medication Determine the efficacy of MR-Guided HIFU in reducing pain medication usage 90 Days No
Primary Complications and Adverse Events Document complications and adverse events as well as the number of unintended lesions that occur as a result of treatment with MR-Guided HIFU. 90 Days Yes
Secondary Changes in bone density Measure changes in bone density between X-ray and CT images taken prior to and following treatment. 90 Days No
Secondary Quality of Life Measure patient quality of life using both the EORTC QLQ-BM22 and FACT-BP scales 90 Days No
See also
  Status Clinical Trial Phase
Completed NCT01833806 - A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain N/A
Terminated NCT01586273 - Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound for Pain Palliation of Bone Metastases N/A
Completed NCT02609828 - Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy Phase 3
Completed NCT04592887 - Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases N/A
Recruiting NCT02231476 - Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients Phase 2
Recruiting NCT02426697 - Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy Phase 3
Completed NCT00334139 - Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Phase 4
Completed NCT01784393 - Chemoradiation for Bone Metastasis Phase 2
Terminated NCT02999152 - Validation of Radio-induced Damage Biomarkers N/A
Not yet recruiting NCT02480634 - Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer Phase 4
Completed NCT02784652 - Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors Phase 2
Completed NCT02774213 - A Study to Collect Data About Analgesia in Patients With Bone Metastasis
Completed NCT02673060 - A Trial of MBC-11 in Patients With CIBD Phase 1
Completed NCT02876731 - Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS) N/A
Recruiting NCT02705157 - The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones N/A
Completed NCT01062503 - Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC N/A
Completed NCT00610272 - Optimization of Radiotherapy in Treatment of Painful Bone Metastasis Phase 3
Completed NCT01998607 - Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw N/A
Recruiting NCT02876991 - Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma N/A
Completed NCT02293642 - Bone Pain Score Validation Initiative